Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective
  10. A Case of Generalized Tetanus With a Short Incubation Period
  11. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index
  12. Does Anti-HIV Positivity in Pregnancy Suggest the Requirement of HIV Prophylaxis for Newborn?

Volume 33, Issue 1

Original Article

Hepatitis A Seroprevalence in Chronic Hepatitis B Patients in Diyarbakir, Turkey

Muhammed Bekçibaşı
Affiliations
  • Bismil Devlet Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Diyarbakır, Türkiye
  • antiHAV IgG
  • Hepatitis A
  • hepatitis B surface antigens

Objective: Hepatitis A virus (HAV) is a common cause of acute viral hepatitis and may lead to serious clinical conditions such as acute liver failure, especially in adulthood. Evaluation of HAV serologies in the patient group with chronic viral hepatitis and to vaccinate susceptible individuals is recommended by the guidelines. The aim of this study was to determine the seroprevalence of anti-HAV IgG in chronic hepatitis B patients who were followed in Bismil State Hospital in Diyarbakır where HBsAg positivity rates are higher than the national average.

Methods: A total of 209 chronic hepatitis B patients, 121 (57.9%) males and 88 (42.1%) females who were followed at the Infectious Diseases and Clinical Micobiology Outpatient Clinic between January 1, 2015 and December 31,2016 were included in the study. Macro-ELISA (Architect i2000 SR, Abbott, Abbott Park, IL, USA) test kits were used to test for anti-HAV IgG, and patients’ data were evaluated retrospectively.

Results: Overall seroprevalence of anti-HAV IgG was 98.6%. Anti-HAV IgG seronegativity was highest in the <20 years of age group as 11.8%, followed by 1.6% in the 20-29 years old age group. Anti-HAV IgG positivity was present in all of the ≥30 years old age groups.

Conclusions: Although anti-HAV IgG positivity is high in adult patients with chronic hepatitis B, HAV screening and vaccination of susceptible individuals should be performed, especially in adolescents and young adults.

Klimik Dergisi 2020; 33(1): 36-8.

Cite this article as: Bekçibaşı M. [Hepatitis A seroprevalence in chronic hepatitis B patients in Diyarbakir, Turkey]. Klimik Derg. 2020; 33(1): 36-8. Turkish.

  • 36-38
  • 10.5152/kd.2020.07
  • April 29, 2020
  • 1365
  • 563
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1